PMID- 27714501
OWN - NLM
STAT- MEDLINE
DCOM- 20170127
LR  - 20231213
IS  - 1432-8798 (Electronic)
IS  - 0304-8608 (Linking)
VI  - 162
IP  - 1
DP  - 2017 Jan
TI  - IL28B rs12980275 and HLA rs4273729 genotypes as a powerful predictor factor for 
      rapid, early, and sustained virologic response in patients with chronic hepatitis 
      C.
PG  - 181-189
LID - 10.1007/s00705-016-3095-1 [doi]
AB  - Single-nucleotide polymorphisms (SNPs) in the Interleukin-28B (IL28B) gene and 
      rs4273729 in the human leukocyte antigen (HLA) gene in chronic hepatitis C (CHC) 
      virus infection are important for predicting treatment outcome. In this study, 
      the distribution of IL28B SNPs (rs12979860 and rs12980275) and HLA rs4273729 in 
      rapid virologic response (RVR), complete early virologic response (cEVR) and 
      sustained virologic response (SVR) in HCV Iranian patients with CHC virus 
      infection was assessed. IL28B genotyping and rs4273729 were performed using the 
      amplification refractory mutation system (ARMS)-PCR and direct sequencing in 190 
      CHC virus infections, respectively. RVR, cEVR, and SVR were 53.2 %, 78.9 %, and 
      65.8 %, respectively. Multivariate regression analysis demonstrated that the 
      responses significantly predicted SVR in patients with age <40 years (p = 0.008), 
      HCV genotypes (p = 0.032), IL28B rs12979860 CC genotype (p < 0.001), rs12980275 
      AA genotype (p < 0.001), rs4273729 GG genotype (p < 0.001), RVR (p < 0.001) and 
      cEVR (p = 0.024). Three critical predictor factors based on RVR response were 
      rs12979860 CC genotype (p = 0.033), rs12980275 AA genotype (p < 0.001) and 
      rs4273729 GG genotype (p < 0.001), while rs12980275 AA (p = 0.003) and rs4273729 
      GG genotypes (p < 0.001) predicted cEVR. For the first time in Iran, these 
      results revealed that the rs12980275 and HLA rs4273729 are important for the 
      treatment of CHC infection. These findings may help predict responses to CHC 
      infection treatment and reduce the cost and side effects of therapy.
FAU - Sedighimehr, Parvaneh
AU  - Sedighimehr P
AD  - Department of Biology, Science and Research Branch, Islamic Azad University, 
      Tehran, Iran.
FAU - Irani, Shiva
AU  - Irani S
AD  - Department of Biology, Science and Research Branch, Islamic Azad University, 
      Tehran, Iran.
FAU - Sakhaee, Fatemeh
AU  - Sakhaee F
AD  - Departments of Mycobacteriology and Pulmonary Research, Pasteur Institute of 
      Iran, Tehran, Iran.
FAU - Vaziri, Farzam
AU  - Vaziri F
AD  - Departments of Mycobacteriology and Pulmonary Research, Pasteur Institute of 
      Iran, Tehran, Iran.
AD  - Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran.
FAU - Aghasadeghi, Mohammadreza
AU  - Aghasadeghi M
AD  - Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.
FAU - Sadat, Seyed Mehdi
AU  - Sadat SM
AD  - Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran.
FAU - Jamnani, Fatemeh Rahimi
AU  - Jamnani FR
AD  - Departments of Mycobacteriology and Pulmonary Research, Pasteur Institute of 
      Iran, Tehran, Iran.
AD  - Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran.
FAU - Fateh, Abolfazl
AU  - Fateh A
AD  - Departments of Mycobacteriology and Pulmonary Research, Pasteur Institute of 
      Iran, Tehran, Iran. afateh2@gmail.com.
AD  - Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran. 
      afateh2@gmail.com.
FAU - Siadat, Seyed Davar
AU  - Siadat SD
AD  - Departments of Mycobacteriology and Pulmonary Research, Pasteur Institute of 
      Iran, Tehran, Iran.
AD  - Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran.
LA  - eng
PT  - Journal Article
DEP - 20161006
PL  - Austria
TA  - Arch Virol
JT  - Archives of virology
JID - 7506870
RN  - 0 (Antiviral Agents)
RN  - 0 (HLA Antigens)
RN  - 0 (interferon-lambda, human)
RN  - 0 (Interferon-alpha)
RN  - 0 (Interleukins)
RN  - 0 (Recombinant Proteins)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
RN  - 49717AWG6K (Ribavirin)
RN  - 9008-11-1 (Interferons)
RN  - Q46947FE7K (peginterferon alfa-2a)
SB  - IM
MH  - Adult
MH  - Antiviral Agents/*therapeutic use
MH  - Cross-Sectional Studies
MH  - Female
MH  - Genotyping Techniques
MH  - HLA Antigens/*genetics
MH  - Hepatitis C, Chronic/*drug therapy/genetics/*immunology
MH  - Humans
MH  - Interferon-alpha/therapeutic use
MH  - Interferons
MH  - Interleukins/*genetics
MH  - Iran
MH  - Male
MH  - Middle Aged
MH  - Polyethylene Glycols/therapeutic use
MH  - *Polymorphism, Single Nucleotide
MH  - Prognosis
MH  - Recombinant Proteins/therapeutic use
MH  - Ribavirin/therapeutic use
MH  - *Sustained Virologic Response
MH  - Time Factors
MH  - Young Adult
EDAT- 2016/10/08 06:00
MHDA- 2017/01/28 06:00
CRDT- 2016/10/08 06:00
PHST- 2016/09/14 00:00 [received]
PHST- 2016/09/29 00:00 [accepted]
PHST- 2016/10/08 06:00 [pubmed]
PHST- 2017/01/28 06:00 [medline]
PHST- 2016/10/08 06:00 [entrez]
AID - 10.1007/s00705-016-3095-1 [pii]
AID - 10.1007/s00705-016-3095-1 [doi]
PST - ppublish
SO  - Arch Virol. 2017 Jan;162(1):181-189. doi: 10.1007/s00705-016-3095-1. Epub 2016 
      Oct 6.